Dr Geoffrey Paul Gros, PHARMD | |
2800 N Highway 190, Covington, LA 70433-9049 | |
(985) 327-6315 | |
(985) 327-6316 |
Full Name | Dr Geoffrey Paul Gros |
---|---|
Gender | Male |
Speciality | Pharmacist |
Location | 2800 N Highway 190, Covington, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124374780 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 19154 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Geoffrey Paul Gros, PHARMD 2800 N Highway 190, Covington, LA 70433-9049 Ph: () - | Dr Geoffrey Paul Gros, PHARMD 2800 N Highway 190, Covington, LA 70433-9049 Ph: (985) 327-6315 |
News Archive
According to new studies commonly used anesthetics may be causing brain damage in people, especially babies who receive them while their brains are still developing.
Results from a pilot study suggest that people with tinnitus benefit from a progressive management program including cognitive behavioral therapy.
Testifying before the United States Senate Special Committee on Aging, Dr. Leonard Wartofsky, president of The Endocrine Society strongly urged lawmakers to increase regulatory oversight of so-called "bioidentical hormones," which have been inaccurately promoted as a safer and more effective alternative to traditional hormone therapies for women.
Among overweight and obese adults, a diet rich in slowly digested carbohydrates, such as whole grains, legumes and other high-fiber foods, significantly reduces markers of inflammation associated with chronic disease, according to a new study by Fred Hutchinson Cancer Research Center.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
› Verified 3 days ago
Anh Thi Phuong Tran, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 437 Saddlebrook Ct, Covington, LA 70435 Phone: 504-430-2213 | |
Paula Bates Fricker, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1107 S Tyler St, Covington, LA 70433 Phone: 985-892-0818 Fax: 985-892-2742 | |
Stan Tran, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 69630 Stirling Blvd, Covington, LA 70433 Phone: 985-327-6261 | |
Dr. Nathaniel Schultz, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 627 W 21st Ave, Covington, LA 70433 Phone: 985-893-0700 | |
Joseph Lawrence Adams, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1203 Business 190, Covington, LA 70433 Phone: 985-893-7476 Fax: 985-893-5688 | |
Mr. Urban Martinez Jr., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1203 Business 190, Covington, LA 70433 Phone: 985-803-7476 |